Speaker

David Sancho is Full Professor at the Spanish National Cardiovascular Research Center (CNIC) in Madrid, where he leads the Immunobiology lab. He specialized in clinical Immunology (2000) as a resident at Hospital La Princesa (Madrid), while doing a basic research PhD (2003) in Universidad Autónoma de Madrid. He took a postdoctoral position at the London Research Institute (Cancer Research UK, 2004-2009), where he found a new C-type lectin (DNGR-1/CLEC9A) that selectively marks the population of human and mouse dendritic cells that cross-present antigens in MHC-I. His work also established the function of DNGR-1/CLEC9A in cross-priming in vivo and as a target for immunotherapy. On his return to Spain (2010) he established his laboratory at the CNIC, where he has analyzed: 1) tissue damage and infection sensing by several C-type lectin receptors expressed by DCs and macrophages; 2) specialized functions of conventional type 1 DCs; 3) metabolic reprogramming in myeloid cells upon innate sensing; and 4) microbiota-derived metabolites in modulation of immune cells and response to disease.

« Go Back